Displaying 1 drug
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Synonyms: … Tafamidis …
Matched Name: … Tafamidis …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval ... [A189717] Tafamidis is structurally similar to diflusinal. …
Matched Salts name: … Tafamidis meglumine …
Matched Categories: … tafamidis ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Name: … Tafamidis …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval ... [A189717] Tafamidis is structurally similar to diflusinal. …
Matched Salts name: … Tafamidis meglumine …
Matched Categories: … tafamidis ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying 1 drug